| Description | This product is a monoclonal antibody derived from Human (Homo sapiens), which can specifically recognize Suppression of tumorigenicity 14. The antibody is expressed with mammalian cell transient expression system, serum-free and purified by affinity chromatography. The purity and integrity are tested via SDS-PAGE and SEC-HPLC analysis. Given an antigen, additional QC measures are also desired such as affinity testing and binding validation. Specifically, the antibody is provided in multiple formats for in vivo and in vitro assays. The Invivo version features greater than 95% purity, ultra-low endotoxin levels (<1 EU/mg or 0.1 EU/mg), and is preservative, stabilizer, and carrier protein-free. |
| Clonality | Monoclonal |
| Host Species | Human |
| Target Species | Human |
| Isotype | IgG |
| Expression Species | HEK293F or CHO |
| Conjugation | None |
| Purity | >95%, determined by SDS-PAGE and/or SEC-HPLC |
| Endotoxin | <1 EU/mg, determined by LAL method |
| Purification | Protein A affinity purified |
| Sterility | 0.2 μM filtered |
| Formulation | PBS, pH 7.4 |
| Preservation | No preservatives |
| Stabilizer | No stabilizers |
| Storage | Store at 4⁰C within a week. For longer storage, aliquot and store at -20⁰C. |
| Application | ELISA; Neut |
| Application Notes | The antibody is recommended for detection of ST14 by ELISA, Neut assays. |
| ELISA | Enzyme-Linked Immunosorbent Assay Protocol |
| WB | Western Blot Protocol |
| FC | Flow Cytometry Protocol |
| Target | ST14 |
| Alternative Name | ST14; suppression of tumorigenicity 14 (colon carcinoma); HAI; MTSP1; SNC19; ARCI11; MT-SP1; PRSS14; TADG15; TMPRSS14; suppressor of tumorigenicity 14 protein; prostamin; serine protease 14; serine protease TADG-15; membrane-type serine protease 1; tumor associated differentially expressed gene 15 protein; tumor-associated differentially-expressed gene 15 protein; suppression of tumorigenicity 14 (colon carcinoma, matriptase, epithin); |
| Gene ID | 6768 |
| UniProt | Q9Y5Y6 |
| Research Area | Signal Pathway; Cancer Research |
